113 related articles for article (PubMed ID: 15577623)
1. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.
Fikkert V; Hombrouck A; Van Remoortel B; De Maeyer M; Pannecouque C; De Clercq E; Debyser Z; Witvrouw M
AIDS; 2004 Oct; 18(15):2019-28. PubMed ID: 15577623
[TBL] [Abstract][Full Text] [Related]
2. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.
Fikkert V; Van Maele B; Vercammen J; Hantson A; Van Remoortel B; Michiels M; Gurnari C; Pannecouque C; De Maeyer M; Engelborghs Y; De Clercq E; Debyser Z; Witvrouw M
J Virol; 2003 Nov; 77(21):11459-70. PubMed ID: 14557631
[TBL] [Abstract][Full Text] [Related]
3. Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
Hombrouck A; Voet A; Van Remoortel B; Desadeleer C; De Maeyer M; Debyser Z; Witvrouw M
Antimicrob Agents Chemother; 2008 Jun; 52(6):2069-78. PubMed ID: 18378713
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.
Lee DJ; Robinson WE
J Virol; 2004 Jun; 78(11):5835-47. PubMed ID: 15140981
[TBL] [Abstract][Full Text] [Related]
5. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics.
Nakahara K; Wakasa-Morimoto C; Kobayashi M; Miki S; Noshi T; Seki T; Kanamori-Koyama M; Kawauchi S; Suyama A; Fujishita T; Yoshinaga T; Garvey EP; Johns BA; Foster SA; Underwood MR; Sato A; Fujiwara T
Antiviral Res; 2009 Feb; 81(2):141-6. PubMed ID: 19027039
[TBL] [Abstract][Full Text] [Related]
6. Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses.
Witmer M; Danovich R
Methods; 2009 Apr; 47(4):277-82. PubMed ID: 19286458
[TBL] [Abstract][Full Text] [Related]
7. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
8. Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.
Kehlenbeck S; Betz U; Birkmann A; Fast B; Göller AH; Henninger K; Lowinger T; Marrero D; Paessens A; Paulsen D; Pevzner V; Schohe-Loop R; Tsujishita H; Welker R; Kreuter J; Rübsamen-Waigmann H; Dittmer F
J Virol; 2006 Jul; 80(14):6883-94. PubMed ID: 16809294
[TBL] [Abstract][Full Text] [Related]
9. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.
Pluymers W; Neamati N; Pannecouque C; Fikkert V; Marchand C; Burke TR; Pommier Y; Schols D; De Clercq E; Debyser Z; Witvrouw M
Mol Pharmacol; 2000 Sep; 58(3):641-8. PubMed ID: 10953059
[TBL] [Abstract][Full Text] [Related]
10. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
[TBL] [Abstract][Full Text] [Related]
11. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
[TBL] [Abstract][Full Text] [Related]
12. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
[TBL] [Abstract][Full Text] [Related]
13. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Boeri E; Spagnuolo V; Cossarini F; Castagna A; Lazzarin A; Clementi M
J Infect Dis; 2011 Dec; 204(11):1811-5. PubMed ID: 21984737
[TBL] [Abstract][Full Text] [Related]
14. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance.
Zahm JA; Bera S; Pandey KK; Vora A; Stillmock K; Hazuda D; Grandgenett DP
Antimicrob Agents Chemother; 2008 Sep; 52(9):3358-68. PubMed ID: 18591263
[TBL] [Abstract][Full Text] [Related]
16. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.
Hazuda DJ; Anthony NJ; Gomez RP; Jolly SM; Wai JS; Zhuang L; Fisher TE; Embrey M; Guare JP; Egbertson MS; Vacca JP; Huff JR; Felock PJ; Witmer MV; Stillmock KA; Danovich R; Grobler J; Miller MD; Espeseth AS; Jin L; Chen IW; Lin JH; Kassahun K; Ellis JD; Wong BK; Xu W; Pearson PG; Schleif WA; Cortese R; Emini E; Summa V; Holloway MK; Young SD
Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11233-8. PubMed ID: 15277684
[TBL] [Abstract][Full Text] [Related]
17. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
[TBL] [Abstract][Full Text] [Related]
18. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.
Ferns RB; Kirk S; Bennett J; Cook PM; Williams I; Edwards S; Pillay D
AIDS; 2009 Oct; 23(16):2159-64. PubMed ID: 19571721
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea.
Kim JY; Kim EJ; Choi JY; Kwon OK; Kim GJ; Choi SY; Kim SS
Clin Microbiol Infect; 2011 Aug; 17(8):1155-9. PubMed ID: 20946407
[TBL] [Abstract][Full Text] [Related]
20. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.
Goethals O; Clayton R; Van Ginderen M; Vereycken I; Wagemans E; Geluykens P; Dockx K; Strijbos R; Smits V; Vos A; Meersseman G; Jochmans D; Vermeire K; Schols D; Hallenberger S; Hertogs K
J Virol; 2008 Nov; 82(21):10366-74. PubMed ID: 18715920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
